<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00003895</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2013-02096</org_study_id>
    <secondary_id>NCI-2013-02096</secondary_id>
    <secondary_id>CDR0000067065</secondary_id>
    <secondary_id>NCI-T98-0081</secondary_id>
    <secondary_id>PPMC-IRB-99-9</secondary_id>
    <secondary_id>99-9</secondary_id>
    <secondary_id>T98-0081</secondary_id>
    <secondary_id>R21CA082614</secondary_id>
    <nct_id>NCT00003895</nct_id>
    <nct_alias>NCT02009657</nct_alias>
  </id_info>
  <brief_title>Vaccine Therapy in Treating HLA-A2 Positive Patients With Melanoma</brief_title>
  <official_title>A Randomized Phase II Trial to Determine the Immune Response to a Mutated gp100 Melanoma Peptide (209-2M) Vaccine in HLA-A2 Positive Patients With a &amp;gt;1mm Melanoma on Initial Biopsy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      This randomized pilot phase II trial studies how well vaccine therapy works in treating human
      leukocyte antigen class 1 histocompatibility, A-2 (HLA-A2) positive patients with melanoma.
      Vaccines made from peptides may help the body build an effective immune response to kill
      tumor cells.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To define the toxicity of administration of gp100: 209-217 (210M) (gp100:209-217[210M]
      peptide vaccine) and the human papillomavirus (HPV) 16 E7(12-20) peptide (HPV16E7:12-20
      peptide vaccine), with adjuvant Montanide ISA-51 (incomplete Freund's adjuvant), to patients
      who present with a primary melanoma &gt; 1 mm thick.

      II. To measure the T-cell response to the modified self-gp100: 209-217 (210M) peptide and the
      unmodified parental glycoprotein 100 (gp100) peptide.

      III. To measure the T-cell response to the control human leukocyte antigen (HLA)-A2.1
      restricted cytotoxic T-lymphocyte (CTL) epitope of papilloma virus HPV16E7:12-20.

      IV. To determine whether analysis of antigen-specific T-cells using specific HLA-A2/peptide
      tetramers is an effective method for monitoring the immune response of patients undergoing
      peptide vaccination and to compare it to enzyme-linked immunosorbent spot (ELISPOT), limiting
      dilution analysis (LDA) and measurement of intracellular cytokine production (fastimmune).

      V. To determine whether there is a difference between the induction of primary
      peptide-specific T-cell immune responses to the self gp100 peptide versus the foreign E7
      peptide.

      VI. To compare the immune response induced by vaccinating every 2 weeks for 6 months (a total
      of 13 vaccinations) vs. every 3 weeks for 6 months (a total of 9 vaccinations).

      OUTLINE: Patients are randomized to 1 of 2 treatment arms.

      ARM A: Patients receive gp100:209-217(210M) peptide vaccine and HPV16E7:12-20 peptide vaccine
      mixed with incomplete Freund's adjuvant subcutaneously (SC) every 2 weeks for 6 months.
      Treatment continues in the absence of disease progression or unacceptable toxicity.

      ARM B: Patients receive gp100:209-217(210M) peptide vaccine and HPV16E7:12-20 peptide vaccine
      mixed with incomplete Freund's adjuvant SC every 3 weeks for 6 months. Treatment continues in
      the absence of disease progression or unacceptable toxicity.

      In both arms, patients undergo sentinel lymph node biopsy approximately 10 days after the
      second vaccination. Patients with positive lymph nodes undergo complete lymph node dissection
      and resume vaccinations.

      After completion of study treatment, patients are followed up every 3 months for 1 year,
      every 4 months for 1 year, every 6 months for 3 years, and then yearly thereafter.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 1999</start_date>
  <completion_date type="Actual">September 2013</completion_date>
  <primary_completion_date type="Actual">September 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>T Cell Immunity to gp100 Peptide and to E7 12-20 Papilloma Virus Peptide</measure>
    <time_frame>Baseline to 6 months</time_frame>
    <description>Frequency measures obtained from each assay will be transformed to (common) logs for purposes of analysis. Repeated measures analyses will be performed on longitudinal data to assess patients' immune response profiles over time. Comparability of assay methods will be assessed with correlation analyses, regression analyses, standard parametric and nonparametric tests, and agreement methods.
Pre- and post-immunization T-cell immunity to g209-2M peptide, to HPV16E7 peptide, and to a negative control HLA-A2 HIV peptide (pol) were assessed using HLA-A2/peptide tetramer-specific binding analysis. Within-subject analyses were performed to determine differences between pre- and postimmunization responses to the g209 -2M and HPV peptides and to the negative control HIV peptide after completion of 6 months of vaccination. Pre- versus postimmunization response differences were used as criterion measures in between-group (among subjects) analyses.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Recurrent Melanoma</condition>
  <condition>Stage IA Melanoma</condition>
  <condition>Stage IB Melanoma</condition>
  <condition>Stage IIA Melanoma</condition>
  <condition>Stage IIB Melanoma</condition>
  <condition>Stage IIC Melanoma</condition>
  <condition>Stage IIIA Melanoma</condition>
  <condition>Stage IIIB Melanoma</condition>
  <condition>Stage IIIC Melanoma</condition>
  <arm_group>
    <arm_group_label>gp100:209-217(210M) + HPV 16 E7:12-20 (every 2 weeks)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive gp100:209-217(210M) peptide vaccine and HPV 16 E7:12-20 peptide vaccine mixed with incomplete Freund's adjuvant SC every 2 weeks for 6 months. Treatment continues in the absence of disease progression or unacceptable toxicity. Patients undergo laboratory biomarker analysis.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>gp100:209-217(210M) + HPV 16 E7:12-20 (every 3 weeks)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive gp100:209-217(210M) peptide vaccine and HPV 16 E7:12-20 peptide vaccine mixed with incomplete Freund's adjuvant SC every 3 weeks for 6 months. Treatment continues in the absence of disease progression or unacceptable toxicity. Patients undergo laboratory biomarker analysis.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>HPV 16 E7:12-20</intervention_name>
    <description>Given SC</description>
    <arm_group_label>gp100:209-217(210M) + HPV 16 E7:12-20 (every 2 weeks)</arm_group_label>
    <arm_group_label>gp100:209-217(210M) + HPV 16 E7:12-20 (every 3 weeks)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>gp100:209-217(210M)</intervention_name>
    <description>Given SC</description>
    <arm_group_label>gp100:209-217(210M) + HPV 16 E7:12-20 (every 2 weeks)</arm_group_label>
    <arm_group_label>gp100:209-217(210M) + HPV 16 E7:12-20 (every 3 weeks)</arm_group_label>
    <other_name>G9 209-2M</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>gp100:209-217(210M) + HPV 16 E7:12-20 (every 2 weeks)</arm_group_label>
    <arm_group_label>gp100:209-217(210M) + HPV 16 E7:12-20 (every 3 weeks)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients must have histologically confirmed primary melanoma of Breslow thickness
             1.0-4.0 mm; patients who have had only their initial biopsy are preferred; however,
             those who have already undergone a wide local excision are also eligible; patients may
             be enrolled up to three months after their wide local excision

          -  Patients whose melanoma is &gt; 4.0 mm thick who have positive or negative regional lymph
             nodes are also eligible

          -  After accrual to the original 26 patient goal, all patients must be enrolled prior to
             sentinel lymph node dissection; patients with previous lymph node dissection will not
             be eligible

          -  Patients must be HLA typed and be shown to be HLA-A2.1+ by either serologic
             techniques, flow cytometry, or molecular techniques

          -  Patients must be ambulatory with good performance status (Karnofsky performance status
             [PS] 80-100)

          -  White blood cell (WBC) &gt;= 3500/mm^3

          -  Platelets (Plt) &gt;= 100,000/mm^3

          -  Hemoglobin &gt;= 9 gm/100 ml

          -  Serum creatinine =&lt; 2 mg/dl

          -  Total bilirubin =&lt; 2.0 mg/dl

          -  Patients must have recovered from any effects of major surgery and be free of
             significant systemic infection

          -  Patients must be negative for human immunodeficiency virus (HIV) antibody by
             enzyme-linked immunosorbent assay (ELISA) (or negative by Western blot if ELISA is
             positive) if they are considered to be at high risk; others do not require serologic
             testing if there are no symptoms or risk factors for HIV disease

          -  Women of childbearing potential must have a negative pregnancy test and should avoid
             becoming pregnant while on treatment

          -  Patients must give written informed consent prior to initiation of therapy; patients
             with a history of major psychiatric illness must be judged able to fully understand
             the investigational nature of the study and the risks associated with the therapy

        Exclusion Criteria:

          -  Patients must not have clinically detectable distant metastases

          -  Patients who require or are likely to require systemic corticosteroids for
             intercurrent illness

          -  Patients with any significant medical disease other than the malignancy (e.g. chronic
             obstructive pulmonary disorder [COPD], patients with ascites or pleural effusions)
             which in the opinion of the investigator would significantly increase the risk of
             immunotherapy

          -  Patient should be free of any other cancers or deemed at low risk for their recurrence
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>17 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Walter J. Urba, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Providence Cancer Center, Earle A. Chiles Research Institute, Robert W. Franz Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Providence Portland Medical Center</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>July 17, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 18, 2003</study_first_posted>
  <results_first_submitted>April 28, 2015</results_first_submitted>
  <results_first_submitted_qc>December 28, 2016</results_first_submitted_qc>
  <results_first_posted type="Actual">February 20, 2017</results_first_posted>
  <last_update_submitted>December 28, 2016</last_update_submitted>
  <last_update_submitted_qc>December 28, 2016</last_update_submitted_qc>
  <last_update_posted type="Actual">February 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>gp100:209-217(210M)and HPV 16 E7:12-20 (Every 2 Weeks)</title>
          <description>Patients receive gp100:209-217(210M) peptide vaccine and HPV 16 E7:12-20 peptide vaccine mixed with incomplete Freund's adjuvant SC every 2 weeks for 6 months. Treatment continues in the absence of disease progression or unacceptable toxicity.
HPV 16 E7:12-20 peptide vaccine: Given SC
gp100:209-217(210M) peptide vaccine: Given SC
laboratory biomarker analysis: Correlative studies</description>
        </group>
        <group group_id="P2">
          <title>gp100:209-217(210M) and HPV 16 E7:12-20 (Every 3 Weeks)</title>
          <description>Patients receive gp100:209-217(210M) peptide vaccine and HPV 16 E7:12-20 peptide vaccine mixed with incomplete Freund's adjuvant SC every 3 weeks for 6 months. Treatment continues in the absence of disease progression or unacceptable toxicity.
HPV 16 E7:12-20 peptide vaccine: Given SC
gp100:209-217(210M) peptide vaccine: Given SC
laboratory biomarker analysis: Correlative studies</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Patient Vacation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Arm A (Every 2 Weeks)</title>
        </group>
        <group group_id="B2">
          <title>Arm B (Every 3 Weeks)</title>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="18"/>
            <count group_id="B2" value="18"/>
            <count group_id="B3" value="36"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="28"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>T Cell Immunity to gp100 Peptide and to E7 12-20 Papilloma Virus Peptide</title>
        <description>Frequency measures obtained from each assay will be transformed to (common) logs for purposes of analysis. Repeated measures analyses will be performed on longitudinal data to assess patients’ immune response profiles over time. Comparability of assay methods will be assessed with correlation analyses, regression analyses, standard parametric and nonparametric tests, and agreement methods.
Pre- and post-immunization T-cell immunity to g209–2M peptide, to HPV16E7 peptide, and to a negative control HLA-A2 HIV peptide (pol) were assessed using HLA-A2/peptide tetramer-specific binding analysis. Within-subject analyses were performed to determine differences between pre- and postimmunization responses to the g209 –2M and HPV peptides and to the negative control HIV peptide after completion of 6 months of vaccination. Pre- versus postimmunization response differences were used as criterion measures in between-group (among subjects) analyses.</description>
        <time_frame>Baseline to 6 months</time_frame>
        <population>Patients were randomly assigned to two different vaccination schedules: group A received vaccinations every 2 weeks for 6 months (13 total injections), and group B received vaccinations every 3 weeks for 6 months (nine total vaccinations).</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A (Every 2 Weeks, gp100:209-217(210M) and HPV 16 E7:12-20)</title>
            <description>Patients receive gp100:209-217(210M) peptide vaccine and HPV 16 E7:12-20 peptide vaccine mixed with incomplete Freund's adjuvant SC every 2 weeks for 6 months. Treatment continues in the absence of disease progression or unacceptable toxicity.
HPV 16 E7:12-20 peptide vaccine: Given SC
gp100:209-217(210M) peptide vaccine: Given SC
laboratory biomarker analysis: Correlative studies</description>
          </group>
          <group group_id="O2">
            <title>Arm B (Every 3 Weeks, gp100:209-217(210M) + HPV 16 E7:12-20)</title>
            <description>Patients receive gp100:209-217(210M) peptide vaccine and HPV 16 E7:12-20 peptide vaccine mixed with incomplete Freund's adjuvant SC every 3 weeks for 6 months. Treatment continues in the absence of disease progression or unacceptable toxicity.
HPV 16 E7:12-20 peptide vaccine: Given SC
gp100:209-217(210M) peptide vaccine: Given SC
laboratory biomarker analysis: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>T Cell Immunity to gp100 Peptide and to E7 12-20 Papilloma Virus Peptide</title>
          <description>Frequency measures obtained from each assay will be transformed to (common) logs for purposes of analysis. Repeated measures analyses will be performed on longitudinal data to assess patients’ immune response profiles over time. Comparability of assay methods will be assessed with correlation analyses, regression analyses, standard parametric and nonparametric tests, and agreement methods.
Pre- and post-immunization T-cell immunity to g209–2M peptide, to HPV16E7 peptide, and to a negative control HLA-A2 HIV peptide (pol) were assessed using HLA-A2/peptide tetramer-specific binding analysis. Within-subject analyses were performed to determine differences between pre- and postimmunization responses to the g209 –2M and HPV peptides and to the negative control HIV peptide after completion of 6 months of vaccination. Pre- versus postimmunization response differences were used as criterion measures in between-group (among subjects) analyses.</description>
          <population>Patients were randomly assigned to two different vaccination schedules: group A received vaccinations every 2 weeks for 6 months (13 total injections), and group B received vaccinations every 3 weeks for 6 months (nine total vaccinations).</population>
          <units>% of CD8+ T cells</units>
          <param>Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>pre-treatment %gp100 g209-2M-specific T cells</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.02" lower_limit="0.01" upper_limit="0.03"/>
                    <measurement group_id="O2" value="0.01" lower_limit="0.00" upper_limit="0.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-treatment % gp100 g209-2M-specific T cells</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.97" lower_limit="0.37" upper_limit="1.57"/>
                    <measurement group_id="O2" value="0.98" lower_limit="0.04" upper_limit="1.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre-Treatment % HPV16:E7 12-20-specific T cells</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.61" lower_limit="0" upper_limit="1.27"/>
                    <measurement group_id="O2" value="0.1" lower_limit="0.04" upper_limit="0.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-Treatment % HPV16:E7 12-20-specific T cells</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.68" lower_limit="0.31" upper_limit="1.05"/>
                    <measurement group_id="O2" value="1.34" lower_limit="0.85" upper_limit="1.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.001</p_value>
            <p_value_desc>Post versus Pre-treatment % g209-2M-specific t-cells</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <p_value_desc>Post versus Pre-Treatment %g209-2M-specific T-cells</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.59</p_value>
            <p_value_desc>Arm A Versus Arm B</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Arm A (Every 2 Weeks)</title>
          <description>Patients receive gp100:209-217(210M) peptide vaccine and HPV 16 E7:12-20 peptide vaccine mixed with incomplete Freund's adjuvant SC every 2 weeks for 6 months. Treatment continues in the absence of disease progression or unacceptable toxicity.
HPV 16 E7:12-20 peptide vaccine: Given SC
gp100:209-217(210M) peptide vaccine: Given SC
laboratory biomarker analysis: Correlative studies</description>
        </group>
        <group group_id="E2">
          <title>Arm B (Every 3 Weeks)</title>
          <description>Patients receive gp100:209-217(210M) peptide vaccine and HPV 16 E7:12-20 peptide vaccine mixed with incomplete Freund's adjuvant SC every 3 weeks for 6 months. Treatment continues in the absence of disease progression or unacceptable toxicity.
HPV 16 E7:12-20 peptide vaccine: Given SC
gp100:209-217(210M) peptide vaccine: Given SC
laboratory biomarker analysis: Correlative studies</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>CVA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Endocrine-Other</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="18"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="18"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="18"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Dysguesia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Dry Mouth</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="18"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="18"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="18"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <description>Headache/Back/Knee etc</description>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="18"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="18"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Neuropathy</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="18"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Injection Site Reaction</sub_title>
                <description>Erythema/Induration/Ecchymosis</description>
                <counts group_id="E1" events="18" subjects_affected="18" subjects_at_risk="18"/>
                <counts group_id="E2" events="17" subjects_affected="17" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Edema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Walter J. Urba, MD, PhD; Physician Director of Research</name_or_title>
      <organization>Providence Cancer Center, Earle A. Chiles Research Institute, Robert W. Franz Cancer Center</organization>
      <phone>503-215-5696</phone>
      <email>Walter.Urba@providence.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

